Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University.
Beijing Key Laboratory of Brian Tumor, Beijing; and.
J Neurosurg. 2017 Sep;127(3):480-491. doi: 10.3171/2016.8.JNS16934. Epub 2016 Nov 11.
OBJECTIVE The natural history of cerebral cavernous malformations (CMs) has been widely studied, but the clinical course of untreated thalamic CMs is largely unknown. Hemorrhage of these lesions can be devastating. The authors undertook this study to obtain a prospective hemorrhage rate and provide a better understanding of the prognosis of untreated thalamic CMs. METHODS This longitudinal cohort study included patients with thalamic CMs who were diagnosed between 2000 and 2015. Clinical data were recorded, radiological studies were extensively reviewed, and follow-up evaluations were performed. RESULTS A total of 121 patients were included in the study (56.2% female), with a mean follow-up duration of 3.6 years. The overall annual hemorrhage rate (subsequent to the initial presentation) was calculated to be 9.7% based on the occurrence of 42 hemorrhages over 433.1 patient-years. This rate was highest in patients (n = 87) who initially presented with hemorrhage and focal neurological deficits (FNDs) (14.1%) (χ = 15.358, p < 0.001), followed by patients (n = 19) with hemorrhage but without FND (4.5%) and patients (n = 15) without hemorrhage regardless of symptoms (1.2%). The initial patient presentations of hemorrhage with FND (hazard ratio [HR] 2.767, 95% CI 1.336-5.731, p = 0.006) and associated developmental venous anomaly (DVA) (HR 2.510, 95% CI 1.275-4.942, p = 0.008) were identified as independent hemorrhage risk factors. The annual hemorrhage rate was significantly higher in patients with hemorrhagic pres entation at diagnosis (11.7%, p = 0.004) or DVA (15.7%, p = 0.002). Compared with the modified Rankin Scale (mRS) score at diagnosis (mean 2.2), the final mRS score (mean 2.0) was improved in 37 patients (30.6%), stable in 59 patients (48.8%), and worse in 25 patients (20.7%). Lesion size (odds ratio [OR] per 0.1 cm increase 3.410, 95% CI 1.272-9.146, p = 0.015) and mRS score at diagnosis (OR per 1 point increase 3.548, 95% CI 1.815-6.937, p < 0.001) were independent adverse risk factors for poor neurological outcome (mRS score ≥ 2). Patients experiencing hemorrhage after the initial ictus (OR per 1 ictus increase 6.923, 95% CI 3.023-15.855, p < 0.001) had a greater chance of worsened neurological status. CONCLUSIONS This study verified the adverse predictors for hemorrhage and functional outcomes of thalamic CMs and demonstrated an overall annual symptomatic hemorrhage rate of 9.7% after the initial presentation. These findings and the mode of initial presentation are useful for clinicians and patients when selecting an appropriate treatment, although the tertiary referral bias of the series should be taken into account.
目的 脑动静脉畸形(CAVM)的自然史已被广泛研究,但未经治疗的丘脑 CAVM 的临床病程在很大程度上尚不清楚。这些病变的出血可能是毁灭性的。作者进行这项研究是为了获得前瞻性出血率,并更好地了解未经治疗的丘脑 CAVM 的预后。
方法 本纵向队列研究纳入了 2000 年至 2015 年间诊断为丘脑 CAVM 的患者。记录临床资料,广泛复习影像学研究,并进行随访评估。
结果 共有 121 名患者纳入研究(56.2%为女性),平均随访时间为 3.6 年。根据 42 例患者在 433.1 个患者年中发生的出血,计算出总的初始表现后年出血率为 9.7%。在最初表现为出血和局灶性神经功能缺损(FND)的患者(n=87)中,出血率最高(14.1%)(χ=15.358,p<0.001),其次是表现为出血但无 FND 的患者(n=19)(4.5%)和无论有无症状均无出血的患者(n=15)(1.2%)。具有 FND 的初始出血表现(危险比[HR]2.767,95%CI 1.336-5.731,p=0.006)和相关的发育性静脉异常(DVA)(HR 2.510,95%CI 1.275-4.942,p=0.008)是独立的出血危险因素。诊断时有出血表现(p=0.004)或 DVA(p=0.002)的患者年出血率显著较高。与诊断时改良 Rankin 量表(mRS)评分(平均 2.2)相比,37 名患者(30.6%)的最终 mRS 评分(平均 2.0)有所改善,59 名患者(48.8%)保持稳定,25 名患者(20.7%)恶化。病灶大小(每增加 0.1cm 的比值比[OR]为 3.410,95%CI 1.272-9.146,p=0.015)和诊断时的 mRS 评分(每增加 1 分的 OR 为 3.548,95%CI 1.815-6.937,p<0.001)是不良神经结局(mRS 评分≥2)的独立不良危险因素。在最初发作后发生出血的患者(OR 每增加 1 次发作增加 6.923,95%CI 3.023-15.855,p<0.001),神经状态恶化的可能性更大。
结论 本研究验证了丘脑 CAVM 出血和功能结局的不良预测因素,并显示初始表现后总的症状性出血率为 9.7%。这些发现和初始表现模式可帮助临床医生和患者在选择适当的治疗方法时参考,尽管应考虑该系列的三级转诊偏倚。